SecBot SecBot
Biotech Drug Report Generated Oct 24, 2026

MGC026

MGNX·MACROGENICS INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1
Time to market
Unknown, still in Phase 1; if successful, Phase 2/3 trials and regulatory review would take several years
Why 4/10
MGC026 is a Phase 1 asset with no pivotal readout or PDUFA in the next ~12 months. The next hard catalyst is the mid-2027 data update (~8 months out), which is not a binary regulatory or pivotal event. The drug is a key pipeline asset but MacroGenics also has other programs (lorigerlimab, MGC030), so MGC026 is not a single-asset binary.
Actionable Insight NEUTRAL

Watch for the early 2027 initiation of the MGC026 + pembrolizumab front-line SCCHN combo study and the mid-2027 Phase 1 data update. The stock's $2.25 price vs. $8 mean analyst target suggests the market is pricing in significant pipeline risk. Monitor competitive B7-H3 ADC data from I-DXd and HS-20093 as benchmarks.

Price Chart

Loading chart...

Executive Summary

MGC026 is MacroGenics' B7-H3-directed antibody-drug conjugate (ADC) currently in Phase 1 development. At ESMO 2026, the company reported interim data showing a 27% best overall response rate (6/22) in heavily pretreated SCCHN patients with no treatment-related discontinuations, a competitive profile versus other B7-H3 ADCs (I-DXd 14%, HS-20093 17%). The company plans to initiate a front-line combo study with pembrolizumab in early 2027 and provide the next data update mid-2027. MacroGenics trades at ~$2.25 (market cap ~$229M) with a mean analyst price target of $8, reflecting ~278% implied upside. However, MGC026 is still early-stage (Phase 1), the B7-H3 ADC space is increasingly competitive, and the company has no approved products, relying on its pipeline and the recent $122.5M manufacturing sale for funding.

How It Works

MGC026 is an antibody-drug conjugate (ADC), a targeted cancer therapy that works like a guided missile. One part of the drug (the antibody) binds to a protein called B7-H3 that is found on the surface of many cancer cells, and the other part delivers a chemotherapy payload directly inside those cells. This approach aims to kill cancer cells while sparing healthy tissue.

Trial Status

Interim Phase 1 data for MGC026 in squamous cell carcinoma of the head and neck (SCCHN) were presented at ESMO 2026. The dose-escalation and expansion cohorts are ongoing. A Simon's 2-stage monotherapy cohort (n=40) is enrolling. The company plans to initiate a front-line SCCHN combination study with pembrolizumab in early 2027, with the next data update expected mid-2027.

The Two-Sided Case

▲ Bull Case4
27% best ORR (6/22) in heavily pretreated SCCHN compares favorably to competing B7-H3 ADCs like I-DXd (14%) and HS-20093 (17%) per the company's 8-K filing
Zero treatment-related discontinuations, ILD, or ocular toxicity, a clean safety profile that supports combination therapy with checkpoint inhibitors
Mean analyst price target of $8 vs. current ~$2.25 stock price implies ~278% upside, with 9 of 14 analysts at Buy/Strong Buy
Recent $122.5M sale of GMP manufacturing to Bora Pharmaceuticals provides non-dilutive capital to fund pipeline without near-term financing risk
▼ Bear Case5
Phase 1 data are preliminary with small sample sizes (n=22 in SCCHN expansion); response rates may change with full enrollment
B7-H3 ADC space is increasingly competitive with multiple programs (I-DXd from Daiichi Sankyo, HS-20093 from Hansoh Pharma, YL201 from YL Biologics) advancing
MacroGenics is pre-revenue with no approved products; reliance on pipeline success and capital markets for funding
Insider sold 31,105 shares at $4.15 in August 2026 via a 10b5-1 plan, and Wasatch Advisors trimmed its position by 37.5% in Q3 2026
Bull/bear evidence scan shows net bearish signal with moderate strength due to high short-volume ratio (~44%) and multiple institutional trims/exits

Upcoming Catalysts

  • Early 2027: Initiation of front-line SCCHN combo study with pembrolizumab
  • Mid-2027: Next MGC026 Phase 1 data update
  • Simon's 2-stage monotherapy cohort (n=40) enrollment completion and data

Source Filing

The SecBot filing or press-release report that triggered this drug report:

MACROGENICS INC 8-K MGNX ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov